Inventor · disambiguated record
Catherine Elisabeth Charron
Also filed as: CHARRON CATHERINE ELISABETH
21 granted patents·6 pending applications·432 citations·filing 2009–2023
96Inventor score
Top patents by PatentIndex Score
27 records- 0197US9108950B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Aug 18, 2015·38 cites·13 claims
- 0296US8642773B2P38MAP kinase inhibitorITO KAZUHIRO·Filed 2010·Granted Feb 4, 2014·44 cites·4 claims
- 0396US8293771B2p38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 23, 2012·49 cites·9 claims
- 0496US8293748B2p38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 23, 2012·47 cites·19 claims
- 0595US8618140B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2012·Granted Dec 31, 2013·41 cites·20 claims
- 0695US8299073B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 30, 2012·50 cites·19 claims
- 0795US8299074B2P38 MAP kinase inhibitorsITO KAZUHIRO·Filed 2009·Granted Oct 30, 2012·48 cites·17 claims
- 0894US8975285B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Mar 10, 2015·26 cites·3 claims
- 0992US10738032B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2019·Granted Aug 11, 2020·3 cites·24 claims
- 1092US9475796B21-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2012·Granted Oct 25, 2016·12 cites·14 claims
- 1192US9249125B2Pyrazole derivatives as p38 MAP inhibitorsRESPIVERT LTD·Filed 2013·Granted Feb 2, 2016·30 cites·12 claims
- 1291US10266519B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2017·Granted Apr 23, 2019·6 cites·11 claims
- 1389US9724347B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2016·Granted Aug 8, 2017·5 cites·17 claims
- 1488US9850231B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitorsRESPIVERT LTD·Filed 2015·Granted Dec 26, 2017·5 cites·8 claims
- 1586US10238658B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2018·Granted Mar 26, 2019·3 cites·19 claims
- 1685US9242960B2P38MAP kinase inhibitorsRESPIVERT LTD·Filed 2014·Granted Jan 26, 2016·6 cites·6 claims
- 1784US9260410B2P38 MAP kinase inhibitorsKING-UNDERWOOD JOHN·Filed 2011·Granted Feb 16, 2016·7 cites·10 claims
- 1883US9993478B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2017·Granted Jun 12, 2018·2 cites·19 claims
- 1983US9701670B2Pyrazolyl-ureas as kinase inhibitorsRESPIVERT LTD·Filed 2013·Granted Jul 11, 2017·10 cites·18 claims
- 2080US2024343711A11-pyrazolyl-3- (4- ((2 -anilinopyrimidin- 4 - yl) oxy) napththalen- i - yl) ureas as p38 mapkinase inhibitorsRESPIVERT LTD·Filed 2023·Application pending·0 cites
- 2169US10813932B21-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitorsRESPIVERT LTD·Filed 2019·Granted Oct 27, 2020·0 cites·18 claims
- 2261US2018000830A1Inhibitors of hemopoietic cell kinase (p-59-hck) and their use in the treatment of influenza infectionRESPIVERT LTD·Filed 2017·Application pending·0 cites
- 2357US2016045512A1Inhibitors of Hemopoietic Cell Kinase (P59-HCK) and Their Use in the Treatment of Influenza InfectionRESPIVERT LTD·Filed 2015·Application pending·0 cites
- 2456US2012244120A1Inhibitors of hemopoietic cell kinase (p59-hck) and their use in the treatment of influenza infectionCHARRON CATHERINE ELISABETH·Filed 2010·Application pending·0 cites
- 2547US10144721B2P38 MAP kinase inhibitorsRESPIVERT LTD·Filed 2016·Granted Dec 4, 2018·0 cites·13 claims
- 2646US2013123260A1MethodsCHARRON CATHERINE ELISABETH·Filed 2011·Application pending·0 cites
- 2744US2016045482A1Ureido-pyrazole derivativesRESPIVERT LTD·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →